Drugs Containing Excipient (Inactive Ingredient) ISOPROPYL ACETATE

Generic drugs containing ISOPROPYL ACETATE excipient

Company	Ingredient	NDC	Excipient
Cosette Pharmaceuticals Inc	ciclopirox	0713-0317	ISOPROPYL ACETATE
Taro Pharmaceuticals USA Inc	ciclopirox	51672-5302	ISOPROPYL ACETATE
NuCare PharmaceuticalsInc	ciclopirox	68071-4977	ISOPROPYL ACETATE

Last updated: August 20, 2026

ecutive summary: Isopropyl acetate is a commodity solvent with a limited but established pharmaceutical role in process chemistry, extraction, granulation, and coating operations. Its financial trajectory is driven by acetic acid and isopropanol costs, regional solvent capacity, coatings and inks demand, and hazardous-material handling requirements rather than pharmaceutical exclusivity. Pharmaceutical demand is unlikely to support meaningful pricing power because qualified alternatives include ethyl acetate, acetone, ethanol, and other Class 3 solvents. No Orange Book patents, drug exclusivity periods, Paragraph IV challenges, or biosimilar issues attach to isopropyl acetate itself.

Isopropyl Acetate Pharmaceutical Excipient Market Dynamics and Financial Trajectory

What is isopropyl acetate and how is it used in pharmaceuticals?

Isopropyl acetate, also called 2-propyl acetate or IPAc, is an ester solvent with CAS Registry Number 108-21-4. It is produced primarily by esterifying acetic acid with isopropanol.

Attribute	Data
Chemical formula	C5H10O2
Molecular weight	102.13 g/mol
CAS number	108-21-4
Boiling point	Approximately 88.5°C
Physical state	Colorless, volatile liquid
Primary function	Organic solvent
Pharmaceutical role	Process solvent, coating solvent, extraction solvent
ICH solvent category	Class 3
Principal commercial markets	Coatings, printing inks, adhesives, chemicals, pharmaceuticals

In pharmaceutical manufacturing, isopropyl acetate is more accurately described as a process solvent than as a high-value finished-product excipient. Potential applications include:

• Solvent systems for film-coating formulations.
• API crystallization and precipitation.
• Liquid-liquid extraction.
• Washing and purification operations.
• Granulation or drying processes where a volatile organic solvent is required.
• Cleaning and manufacturing operations under validated procedures.

Its low boiling point supports relatively rapid removal during drying. Its moderate polarity provides a solvent profile different from acetone, ethanol, and ethyl acetate. Selection depends on API solubility, polymorph control, residual-solvent limits, process safety, and compatibility with coating polymers.

What is the FDA and ICH regulatory status of isopropyl acetate?

Isopropyl acetate is not an active pharmaceutical ingredient. It does not receive FDA drug approval, new chemical entity exclusivity, or biologic exclusivity.

ICH Q3C classifies isopropyl acetate as a Class 3 residual solvent. Class 3 solvents have lower toxicological concern than Class 1 and Class 2 solvents, but manufacturers must still control residual levels under an appropriate pharmaceutical quality system (International Council for Harmonisation, 2021).

The regulatory consequences are practical:

1. Isopropyl acetate must be identified in the manufacturing process and controlled as a residual solvent where relevant.
2. Finished-product specifications and analytical methods must demonstrate compliance with applicable limits.
3. GMP documentation must address supplier qualification, material identity, lot traceability, storage, and contamination controls.
4. A change from another solvent to isopropyl acetate can require process validation, stability work, and regulatory filing depending on the product and jurisdiction.

The FDA Inactive Ingredient Database is the relevant reference for determining whether a substance has precedent in approved drug products and dosage forms. Inclusion, where applicable, does not create exclusivity or approval for a particular supplier. FDA treatment of an inactive ingredient remains product-specific and route-specific (U.S. Food and Drug Administration, n.d.-a).

What is the market size for pharmaceutical-grade isopropyl acetate?

No reliable public source separately reports the global pharmaceutical market for isopropyl acetate. Public market research usually combines pharmaceutical, coatings, inks, adhesives, and chemical uses into broader solvent or ester-solvent categories.

This distinction matters. Pharmaceutical demand is a small part of the total market, while coatings, printing inks, and industrial formulations account for a larger share of consumption. A supplier therefore competes primarily in a commodity solvent market, not a specialty pharmaceutical excipient market.

The commercial market has four layers:

Market layer	Commercial characteristics
Commodity isopropyl acetate	Price-driven, high supplier substitution
High-purity solvent	Higher testing and documentation requirements
GMP or pharmaceutical supply	Qualification, change control, traceability, and audit costs
Formulation-specific grade	Potentially higher margin where process validation limits substitution

A pharmaceutical-grade designation can support a premium over industrial material, but the premium depends on more than assay. Buyers may require:

• Certificate of analysis by lot.
• Water, acidity, nonvolatile residue, and impurity limits.
• Residual-solvent and elemental-impurity data.
• GMP or ISO certifications.
• Supply-chain change notification.
• Container-closure compatibility.
• Validated transport and storage controls.
• Audit access and regulatory support.

These requirements create switching costs after qualification. They do not eliminate competition from other manufacturers or from alternative solvents.

What drives the financial trajectory of isopropyl acetate?

Isopropyl acetate financial performance is principally a margin-management issue. The largest variables are feedstock prices, plant utilization, freight, energy, and the product mix between bulk industrial sales and higher-specification grades.

Feedstock exposure

The main feedstocks are acetic acid and isopropanol. Acetic acid pricing is linked to methanol, carbon monoxide, natural gas, and regional petrochemical capacity. Isopropanol pricing is influenced by propylene, refinery operations, acetone supply, and regional demand.

A simplified cost model is:

Cost or revenue factor	Directional impact
Higher acetic acid cost	Raises production cost
Higher isopropanol cost	Raises production cost
Lower plant utilization	Raises unit conversion cost
Higher energy prices	Reduces gross margin
Tight regional supply	Supports price increases
Excess Asian capacity	Pressures export prices
Higher freight or dangerous-goods charges	Reduces delivered margin
Pharmaceutical qualification	Supports a premium
Greater use of alternative solvents	Caps pricing power

Because isopropyl acetate is a solvent with multiple substitutes, cost increases cannot always be passed through immediately. Producers with integrated feedstocks, local distribution, and efficient esterification capacity have stronger margin protection.

Demand exposure

The main demand sectors are coatings, inks, adhesives, and chemical processing. Pharmaceutical demand is more stable but smaller. This creates a mixed financial profile:

• Industrial demand determines volume.
• Pharmaceutical demand supports product quality and documentation premiums.
• Coatings and ink cycles influence capacity utilization.
• Construction, automotive, packaging, and manufacturing activity affect solvent consumption.
• Environmental rules can shift demand toward waterborne or lower-VOC systems.

A pharmaceutical supplier with a diversified customer base is less exposed to any single drug product or contract-manufacturing program.

How does isopropyl acetate compare with competing pharmaceutical solvents?

Isopropyl acetate competes with several solvents that are already familiar to pharmaceutical process-development teams.

Solvent	Relative commercial position	Main advantage	Main limitation
Isopropyl acetate	Commodity ester solvent	Volatility and solvent selectivity	Flammability and VOC status
Ethyl acetate	Widely used ester solvent	Broad pharmaceutical acceptance and availability	Different solubility and evaporation profile
Acetone	High-volume solvent	Fast evaporation and broad availability	Strong solvency and process-specific compatibility
Ethanol	Common pharmaceutical solvent	Regulatory familiarity and broad formulation use	Higher boiling point and water sensitivity
Isopropanol	Common process solvent	Established supply chain	Different polarity and evaporation behavior
Heptane	Hydrocarbon solvent	Useful for nonpolar processes	Higher toxicological and environmental scrutiny
Methanol	Strong process solvent	Low cost and high solvency	Class 2 residual-solvent restrictions

Ethyl acetate is often the closest commercial substitute. A switch between ethyl acetate and isopropyl acetate can affect crystallization, phase separation, drying rate, coating performance, and impurity profiles. The alternative is not automatically interchangeable from a regulatory or validation perspective.

What patents protect isopropyl acetate pharmaceutical applications?

No core composition-of-matter patent protects isopropyl acetate as a commercial chemical. The molecule has long been known and is manufactured through established esterification chemistry.

Potential intellectual-property rights may instead cover:

• A pharmaceutical formulation that uses isopropyl acetate.
• A specific API crystallization process.
• A coating composition containing isopropyl acetate.
• A manufacturing sequence using isopropyl acetate as an extraction or washing solvent.
• A solvent-recovery system or process-control method.
• A particular grade, impurity profile, or purification method.

Such rights would generally protect a specific process or drug product, not the sale of isopropyl acetate as a chemical. A supplier’s commercial freedom to sell the solvent is therefore usually broader than a drug manufacturer’s freedom to use it in a patented manufacturing route.

Are there Orange Book listings or Paragraph IV challenges?

Isopropyl acetate is not an FDA-approved drug and does not have an Orange Book listing. There is no drug-specific patent term, FDA exclusivity period, Paragraph IV certification, or generic-launch timetable for the solvent itself (U.S. Food and Drug Administration, n.d.-b).

Paragraph IV risk may arise only indirectly when a generic manufacturer challenges a drug patent covering a process or formulation that uses isopropyl acetate. The relevant patent would be listed against the drug product, not against the solvent.

When does isopropyl acetate lose exclusivity?

Isopropyl acetate has no pharmaceutical exclusivity period to expire. Its commercial status is effectively open competition, subject to chemical regulations, product specifications, manufacturing capacity, and contractual restrictions.

The absence of exclusivity produces a different competitive structure from an active pharmaceutical ingredient:

• No five-year new chemical entity exclusivity.
• No three-year clinical-investigation exclusivity.
• No orphan-drug exclusivity.
• No patent cliff linked to the solvent.
• No biosimilar pathway.
• No single originator controlling the market.

Supply agreements, proprietary grades, and customer qualification can create temporary commercial advantages. These are contractual or operational barriers, not statutory exclusivity.

What manufacturing and IP barriers affect pharmaceutical-grade supply?

The manufacturing process itself is relatively mature. The principal barriers are operational:

1. Flammable-liquid handling and storage.
2. Vapor control and worker-safety systems.
3. Residual-solvent testing.
4. Water and impurity control.
5. Batch consistency.
6. Dangerous-goods transportation.
7. Regional environmental permits.
8. Customer qualification and audit requirements.
9. Supply continuity during plant outages.
10. Regulatory change-control obligations.

Environmental compliance is a growing cost factor. Isopropyl acetate is a volatile organic compound and a flammable solvent. Facilities must manage emissions, fire risk, worker exposure, and hazardous-material transport under applicable national and regional rules. The European Chemicals Agency identifies requirements associated with registration, classification, labeling, and safe use under the EU chemicals framework (European Chemicals Agency, n.d.).

These requirements favor established producers and distributors with solvent infrastructure. They do not create durable patent barriers.

Which companies compete in the isopropyl acetate market?

The competitive field includes large chemical companies, regional ester-solvent manufacturers, and distributors. Publicly visible market participants have included Eastman and multiple Asian producers and distributors, although product availability and manufacturing ownership can change by region.

The relevant competitive variables are:

• Regional production capacity.
• Access to acetic acid and isopropanol.
• Bulk storage and terminal infrastructure.
• Pharmaceutical documentation.
• Ability to supply drums, totes, and tankers.
• Contract manufacturing and private-label capacity.
• Regulatory support in the customer’s jurisdiction.
• Delivery reliability.

Eastman lists isopropyl acetate among its solvent products and markets solvent capabilities across industrial applications (Eastman Chemical Company, n.d.). The broader supplier base limits the ability of any single producer to set pharmaceutical-market pricing.

What generic-entry risks exist for products using isopropyl acetate?

Generic-entry risk is product-specific. Isopropyl acetate itself does not create a generic barrier or launch opportunity.

For a drug manufacturer, risk may arise if:

• A formulation patent claims a coating system containing the solvent.
• A process patent claims a crystallization step using isopropyl acetate.
• A regulatory filing discloses a solvent-dependent manufacturing route.
• A supplier disruption forces a process change before patent expiry.
• A generic applicant develops a non-infringing process using ethyl acetate, acetone, or another solvent.

A solvent substitution can reduce patent exposure but may create new regulatory work. Changes can affect impurity formation, particle size, polymorphism, residual solvent, yield, and product stability.

What is the commercial outlook for isopropyl acetate?

The base case is steady, low-to-moderate volume growth with limited structural pricing power. Pharmaceutical demand should remain resilient because validated manufacturing processes are costly to change. Overall financial performance will remain more sensitive to industrial solvent cycles and feedstock spreads than to pharmaceutical consumption.

The strongest commercial opportunities are:

• High-purity and documented grades.
• Regional supply close to pharmaceutical manufacturing clusters.
• Packaged quantities for development and small-batch production.
• Reliable supply for contract development and manufacturing organizations.
• Solvent-recovery and recycling services.
• Technical support for formulation and process qualification.

The weakest position is undifferentiated bulk supply sold solely on price. Producers in this segment face substitution, imported competition, freight volatility, and feedstock exposure.

Key takeaways

• Isopropyl acetate is a Class 3 solvent under ICH Q3C, not a protected pharmaceutical active ingredient.
• Its pharmaceutical role is mainly process-based: coating, extraction, crystallization, washing, and manufacturing.
• No Orange Book listing, drug exclusivity period, Paragraph IV challenge, or biosimilar pathway applies to the solvent itself.
• The market is controlled by commodity solvent economics, not pharmaceutical patent rights.
• Acetic acid, isopropanol, energy, plant utilization, freight, and environmental compliance determine margins.
• Ethyl acetate is the closest common substitute, but substitution can require process validation and regulatory assessment.
• Pharmaceutical-grade documentation can support a premium, although the premium is limited by alternative solvents and multiple suppliers.
• The financial outlook is stable rather than high-growth, with better margins in qualified, documented, and regionally reliable supply.

FAQs about pharmaceutical isopropyl acetate

Is isopropyl acetate an approved pharmaceutical excipient?

It is used as a pharmaceutical manufacturing solvent and may have inactive-ingredient precedent in specific products or dosage forms. Each use must be assessed against applicable FDA and jurisdictional requirements.

What residual-solvent limit applies to isopropyl acetate?

ICH Q3C places isopropyl acetate in Class 3. The applicable concentration and control strategy depend on the product, process, daily dose, and adopted regional guidance.

Can ethyl acetate replace isopropyl acetate in a drug process?

It may be technically feasible, but replacement can alter solubility, crystallization, drying, impurity formation, and polymorph control. The change generally requires documented process and regulatory evaluation.

Does isopropyl acetate have a pharmaceutical patent cliff?

No. The solvent has no drug-like exclusivity period. Patent exposure can arise only from a particular formulation, manufacturing method, or drug product using the solvent.

Is pharmaceutical-grade isopropyl acetate a high-margin specialty chemical?

Usually not. It can earn a documentation and qualification premium over industrial material, but competition, solvent substitution, and commodity feedstock economics limit sustained pricing power.

References

Eastman Chemical Company. (n.d.). Isopropyl acetate. https://www.eastman.com

European Chemicals Agency. (n.d.). Substance information: Isopropyl acetate. https://echa.europa.eu

International Council for Harmonisation. (2021). Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org

U.S. Food and Drug Administration. (n.d.-a). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book